Preview

Medical alphabet

Advanced search

Significance of new semi-quantitative express-test on procalcitonin in determining severity of community-acquired pneumonia

https://doi.org/10.33667/2078-5631-2020-27-11-13

Abstract

The aim of this study was to investigate the association of a new semi-quantitative indicators express-test on procalcitonin and traditional markers of severity of community-acquired pneu monia with bilateral lung involvement in this disease. Materials and methods. In our one-stage comparative study, 123 patients took part. According to the survey, the participants were divided into two subgroups: patients with unilateral community-acquired pneumonia (n = 103) and two-way community-acquired pneumonia (n = 20). The average age of patients in the subgroup with unilateral pneumonia was 49.0 ± 21.0 (M ± SD) years, in the subgroup with bilateral pneumonia 54.0 ± 22.0 years (M ± SD), p = 0.56. Results. Bilateral community-acquired pneumonia in comparison with unilateral pneumonia proceeded with more pronounced increased level procalcitonin rapid test (p = 0.001), while traditional markers (leukocytes, ESR, CRP, fibrinogen) were not associated with the severity of pneumonia and did not differ among themselves in both groups (p = 0.124, p = 0.082, p = 0.814 and p = 0.258 respectively).

About the Authors

K. Yu. Nikolaev
Institute for Cytology and Genetics
Russian Federation
Novosibirsk


O. V. Tsygankova
Institute for Cytology and Genetics; Novosibirsk State Medical University
Russian Federation
Novosibirsk


S. S. Bayramova
Institute for Cytology and Genetics
Russian Federation
Novosibirsk


References

1. Авдеев С. Н., Баймаканова Г. Е., Зубаирова П. А. и др. Роль С-реактивного белка в диагностике бактериальной инфекции и пневмонии у пациентов с обострением хронической обструктивной болезни легких. Пульмонология. 2010; 2: 49–55.

2. Биличенко Т. Н., Чучалин А. Г. Заболеваемость и смертность населения России от острых респираторных вирусных инфекций, пневмонии и вакцинопрофилактика. Терапевтический архив. 2018; (1): 22–26.

3. Кочегарова Е. Ю., Колосов В. П. Значение прокальцитонина и цитокинов в прогнозировании осложненного течения внебольничной пневмонии. Бюллетень. 2011. (40): 48–51.

4. Davies J. Procalcitonin. J Clin Pathol. 2015; 68(9): 675–9. DOI: 10.1136/jclinpath-2014–202807.

5. Finch S., Keir H. R., Dicker A. J. et al. The past decade in bench research into pulmonary infectious diseases: What do clinicians need to know? Respirology. 2017. 22: 1062–1072. DOI: 10.1111/resp.13106.

6. Karhu J, Ala-Kokko TI, Vuorinen T. et al. Interleukin-5, interleukin-6, interferon induced protein-10, procalcitonin and C-reactive protein among mechanically ventilated severe community-acquired viral and bacterial pneumonia patients. Cytokine. 2019; 113:272–276. DOI: 10.1016/j.cyto.2018.07.019.

7. Liu G. B., Cui X. Q., Wang Z. B. et al. Detection of serum procalcitonin and hypersensitive C-reactive protein in patients with pneumonia and sepsis. J Biol Regul Homeost Agents. 2018; 32 (5): 1165–1169.

8. Pantzaris N. D., Spilioti D. X., Psaromyalou A. et al. The Use of Serum Procalcitonin as a Diagnostic and Prognostic Biomarker in Chronic Obstructive Pulmonary Disease Exacerbations: A Literature Review Update. J Clin Med Res. 2018; 10 (7): 545–551. DOI: 10.14740/jocmr3458w

9. Shaddock E. J. How and when to use common biomarkers in community-acquired pneumonia. Pneumonia (Nathan). 2016; 8:17. DOI: 10.1186/s41479-016-0017-7.

10. Titova E., Christensen А., Henriksen A. H. Comparison of procalcitonin, C-reactive protein, white blood cell count and clinical status in diagnosing pneumonia in patients hospitalized with acute exacerbations of COPD: A prospective observational study. Chronic Respiratory Disease. 2019; 16: 1–9. DOI: 10.1177/1479972318769762.


Review

For citations:


Nikolaev K.Yu., Tsygankova O.V., Bayramova S.S. Significance of new semi-quantitative express-test on procalcitonin in determining severity of community-acquired pneumonia. Medical alphabet. 2020;(27):11-13. (In Russ.) https://doi.org/10.33667/2078-5631-2020-27-11-13

Views: 331


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 2078-5631 (Print)
ISSN 2949-2807 (Online)